79
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          5-Hydroxytryptamine 2A receptors (5-HT 2A-Rs) are G-protein coupled receptors. In agreement with their location in the brain, they have been implicated not only in various central physiological functions including memory, sleep, nociception, eating and reward behaviors, but also in many neuropsychiatric disorders. Interestingly, a bidirectional link between depression and epilepsy is suspected since patients with depression and especially suicide attempters have an increased seizure risk, while a significant percentage of epileptic patients suffer from depression. Such epidemiological data led us to hypothesize that both pathologies may share common anatomical and neurobiological alteration of the 5-HT 2A signaling. After a brief presentation of the pharmacological properties of the 5-HT 2A-Rs, this review illustrates how these receptors may directly or indirectly control neuronal excitability in most networks involved in depression and epilepsy through interactions with the monoaminergic, GABAergic and glutamatergic neurotransmissions. It also synthetizes the preclinical and clinical evidence demonstrating the role of these receptors in antidepressant and antiepileptic responses.

          Related collections

          Most cited references201

          • Record: found
          • Abstract: found
          • Article: not found

          Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

          Hallucinogens, including mescaline, psilocybin, and lysergic acid diethylamide (LSD), profoundly affect perception, cognition, and mood. All known drugs of this class are 5-HT(2A) receptor (2AR) agonists, yet closely related 2AR agonists such as lisuride lack comparable psychoactive properties. Why only certain 2AR agonists are hallucinogens and which neural circuits mediate their effects are poorly understood. By genetically expressing 2AR only in cortex, we show that 2AR-regulated pathways on cortical neurons are sufficient to mediate the signaling pattern and behavioral response to hallucinogens. Hallucinogenic and nonhallucinogenic 2AR agonists both regulate signaling in the same 2AR-expressing cortical neurons. However, the signaling and behavioral responses to the hallucinogens are distinct. While lisuride and LSD both act at 2AR expressed by cortex neurons to regulate phospholipase C, LSD responses also involve pertussis toxin-sensitive heterotrimeric G(i/o) proteins and Src. These studies identify the long-elusive neural and signaling mechanisms responsible for the unique effects of hallucinogens.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Identification of a serotonin/glutamate receptor complex implicated in psychosis.

            The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception. Some antipsychotic drugs were identified by their high affinity for serotonin 5-HT2A receptors (2AR). Drugs that interact with metabotropic glutamate receptors (mGluR) also have potential for the treatment of schizophrenia. The effects of hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble some of the core symptoms of schizophrenia. Here we show that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex. The 2AR-mGluR2 complex triggers unique cellular responses when targeted by hallucinogenic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural responses. In post-mortem human brain from untreated schizophrenic subjects, the 2AR is upregulated and the mGluR2 is downregulated, a pattern that could predispose to psychosis. These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.

              Serotonin (5-hydroxytryptamine, 5-HT) is a monoaminergic neurotransmitter that is believed to modulate numerous sensory, motor and behavioural processes in the mammalian nervous system. These diverse responses are elicited through the activation of a large family of receptor subtypes. The complexity of this signalling system and the paucity of selective drugs have made it difficult to define specific roles for 5-HT receptor subtypes, or to determine how serotonergic drugs modulate mood and behaviour. To address these issues, we have generated mutant mice lacking functional 5-HT2C receptors (previously termed 5-HT1C), prominent G-protein-coupled receptors that are widely expressed throughout the brain and spinal cord and which have been proposed to mediate numerous central nervous system (CNS) actions of serotonin. Here we show that 5-HT2C receptor-deficient mice are overweight as a result of abnormal control of feeding behaviour, establishing a role for this receptor in the serotonergic control of appetite. Mutant animals are also prone to spontaneous death from seizures, suggesting that 5-HT2C receptors mediate tonic inhibition of neuronal network excitability.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                17 March 2015
                2015
                : 6
                : 46
                Affiliations
                [1] 1CNRS, Centre de Recherches sur la Cognition Animale, UMR 5169, Toulouse France
                [2] 2CNRS, Centre de Recherches sur la Cognition Animale Université de Toulouse 3, UMR 5169, Toulouse, France
                [3] 3INSERM U1178 Team ≪Depression and Antidepressants≫ Faculté de Pharmacie Paris Sud, Châtenay-Malabry, France
                [4] 4Neurophysiology Unit, Laboratory for the Study of Neurological Disorders, Department of Physiology and Biochemistry, University of Malta, Msida Malta
                [5] 5School of Biosciences, University of Cardiff, Cardiff UK
                Author notes

                Edited by: Alfredo Meneses, Center for Research and Advanced Studies, Mexico

                Reviewed by: Alfredo Meneses, Center for Research and Advanced Studies, Mexico; Luigia Trabace, University of Foggia, Italy

                *Correspondence: Bruno P. Guiard, CNRS, Centre de Recherches sur la Cognition Animale, UMR 5169, Bât 4R3, 118 Route de Narbonne, 31062 Toulouse cedex, France bruno.guiard@ 123456univ-tlse3.fr ; Giuseppe Di Giovanni, Neurophysiology Unit, Laboratory for the Study of Neurological Disorders, Department of Physiology and Biochemistry, University of Malta, Msida MSD 2080, Malta giuseppe.digiovanni@ 123456um.edu.mt

                This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2015.00046
                4362472
                25852551
                8086e661-f948-4db7-aceb-638b8b4b6c19
                Copyright © 2015 Guiard and Di Giovanni.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 18 January 2015
                : 24 February 2015
                Page count
                Figures: 2, Tables: 3, Equations: 0, References: 215, Pages: 17, Words: 0
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                5-ht,5-ht2a receptor,antidepressants,antipsychotics,depression,epilepsy

                Comments

                Comment on this article